Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | DRD1 | P21728 | 4/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD5 | P21918 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1666926 | 0.84 | DRD1 (0.60) | ALDH1A1HSD17B10DRD1DRD2DRD4 | |
| SCHEMBL28403958 | 0.83 | DRD1 (0.45) | ALDH1A1HSD17B10DRD1DRD2DRD4 | |
| SCHEMBL1242872 | 0.82 | DRD1 (0.44) | ALDH1A1HSD17B10DRD1DRD2DRD4 | |
| SCHEMBL29733602 | 0.82 | DRD1 (0.58) | ALDH1A1HSD17B10DRD1DRD2DRD4 | |
| SCHEMBL29733609 | 0.82 | DRD1 (0.58) | ALDH1A1HSD17B10DRD1DRD2DRD4 | |
| SCHEMBL6480845 | 0.82 | ALDH1A1 (0.83) | ALDH1A1HSD17B10L3MBTL1HDAC3HDAC4 | |
| SCHEMBL35966 | 0.80 | ALDH1A1 (0.59) | ALDH1A1HSD17B10DRD1DRD2DRD4 | |
| SCHEMBL31264295 | 0.79 | ALDH1A1 (0.79) | ALDH1A1HSD17B10L3MBTL1HDAC3HDAC4 | |
| SCHEMBL3391465 | 0.79 | DRD1 (0.43) | ALDH1A1HSD17B10DRD1DRD2DRD4 | |
| SCHEMBL5334373 | 0.79 | ALDH1A1 (0.52) | ALDH1A1HSD17B10L3MBTL1CYP2A6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20100216849-A1 | BIPHENYLCARBOXAMIDES | DUNKEL RALF | 2010-08-26 | — | — | US | disclosed |
| US-7728019-B2 | Biphenylcarboxamides | BAYER CROPSCIENCE AG (DE) | 2010-06-01 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7439261-B2 | Process for the preparation of valsartan and intermediates thereof | DIPHARMA S.P.A. (IT) | 2008-10-21 | — | — | US | disclosed |
| US-20080085924-A1 | Biphenylcaboxamides | BAYER CROPSCINCE AG (DE) | 2008-04-10 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1711617-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTICS COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005064008-A9 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES INC (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES. INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005064008-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1533305-A1 | A process for the preparation of valsartan and intermediates thereof | Dipharma S.p.A. (IT) | 2005-05-25 | — | — | EP | disclosed |
| EP-1509537-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085924-A1 | Biphenylcaboxamides | AHR, Q6ZSR9, DDT | ALDH1A1 415/4885HSD17B10 1998/4885DRD1 477/4885 |
| US-20100216849-A1 | BIPHENYLCARBOXAMIDES | AHR, DDT, MRPL21 | ALDH1A1 478/4885HSD17B10 1506/4885DRD1 462/4885 |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | PPA1, PPME1, PNP | ALDH1A1 3361/4885HSD17B10 1783/4885DRD1 4672/4885 |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | ALDH1A1 3232/4885HSD17B10 156/4885DRD1 4109/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | ALDH1A1 3337/4885HSD17B10 1703/4885DRD1 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.